B Cells antibody | FMC7
Filter by Application:F Reset
Mouse anti Human B Cells:FITC
- Product Type
- Monoclonal Antibody
- B Cells
- (FMC7 ANTIGEN)
|Mouse anti Human B cells antibody, clone FMC7 recognizes a glycoprotein antigen of ~105 kDa expressed by B lymphocytes. The FMC7 antigen is expressed by peripheral B lymphocytes. Mouse anti Human B cells antibody, clone FMC7 has been used extensively to differentiate various types of B cell malignancy. B-CLL is generally considered to be negative for FMC7 expression, but strong staining is seen in many other types of B cell lymphoma, including prolymphocytic leukemia and hairy cell leukemia.
The expression pattern of the FMC7 antigen closely corresponds to that seen with CD22. Mouse anti Human B cells antibody, clone FMC7 recognizes a conformational epitope on the CD20 molecule, most likely a multimeric complex of CD20 (Serke et al. 2001). Identity of CD20 as the antigen recognized by Mouse anti Human B cells antibody, clone FMC7 was further confirmed by strong recognition of recombinant CD20 expressed in hematopoietic and non-haematopoietic cell lines and abolition of binding in CD20 extracellular domain mutations. The recognized epitope has also been shown to be cholesterol dependent (Polyak et al. 2003).
- Target Species
- Product Form
- Purified IgM conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Purified IgM prepared by gel filtration from ascites
- Buffer Solution
- TRIS buffered glycine
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
0.2% Bovine Serum Albumin
- HRIK cells - Human B-Lymphoblastoid line.
- Max Ex/Em
Fluorophore Excitation Max (nm) Emission Max (nm) FITC 490 525
- For research purposes only
- 12 months from date of despatch
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
|Application Name||Verified||Min Dilution||Max Dilution|
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
How to Use the SpectraviewerWatch the Tool Tutorial Video ▸
- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
Brooks, D.A. et al. (1981) Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes.
J Immunol. 126 (4): 1373-7.
References for B Cells antibody
Catovsky, D. et al. (1981) Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7.
Blood. 58 (2): 406-8.
Serke, S. et al. (2001) Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: Evidence from phenotyping after Rituxan therapy and transfectant cell analyses.
Cytometry (Comm. Clin. Cytometry) 46:98-104
Zola H., et al. (1984) The human B cell lineage studied with monoclonal antibodies.
In Leucocyte Typing Ed.A. Bernard, Springer Verlag. p363-71.
Zola, H. et al. (1984) The antigen of mature human B cells detected by the monoclonal antibody FMC7: studies on the nature of the antigen and modulation of its expression.
J Immunol. 133 (1): 321-6.
Bloem, A.C. et al. (1988) Functional properties of human B cell subpopulations defined by monoclonal antibodies HB4 and FMC7.
J Immunol. 140 (3): 768-73.
Zola, H. et al. (1987) Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules.
Dis Markers. 5 (4): 227-35.
Ghia, P. et al. (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
Blood. 101 (4): 1262-9.
Ferro LM & Zola H (1990) Modulation of expression of the antigen identified by FMC7 upon human B-lymphocyte activation: evidence for differences between activation in vivo and in vitro.
Immunology. 69 (3): 373-8.
View The Latest Product References
Collins, R.J. et al. (1983) Malignant lymphoma: reactive with the monoclonal antibody fmc-7
Pathology. 15 (3): 350-1. (Conference abstract).
Zucchetto A et al. (2006) A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
J Cell Physiol. 207 (2): 354-63.
Wang, C. et al. (2002) Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5(-) CLL.
Leuk Res. 26 (12): 1125-9.
Amato, D. et al. (2007) Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis.
Am J Clin Pathol. 128 (2): 333-8.
Polyak, M.J. et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.
Leukemia. 17 (7): 1384-9.
Domingo-Domènech, E. et al. (2002) CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.
Haematologica. 87 (10): 1021-7.
Gladkikh, A. et al. (2010) Cyclin D1 expression in B-cell lymphomas.
Exp Hematol. 38 (11): 1047-57.
Unruh, T.L. et al. (2005) Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
Immunology. 116 (2): 223-32.
Gladkikh, A.A. et al. (2017) Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
Cancer Med. 6 (12): 2984-97.
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up